• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

    9/18/25 9:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email

    Believe Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform

    Reiterate Intent to Vote Against Reverse Stock Split at September 19th Special Meeting

    ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.6 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today issued a statement in response to the Company's appointment of W. Mark Watson as Lead Independent Director of the Company's Board of Directors (the "Board") and intent to adopt a stock ownership policy for directors.

    The Concerned Vaxart Stockholders simply do not believe that the elevation of Mr. Watson to a leadership position in the boardroom delivers sufficient change to address stockholder concerns. During Mr. Watson's three-year tenure on the Board, stockholders have endured repeated dilution, governance failures and strategic missteps. We believe designating Mr. Watson as Lead Independent Director conflates title with substance, as true independence requires impartial oversight and freedom from entrenched influence, standards he cannot meet in our view. This appointment underscores the Board's preference for optics rather than meaningful reform, and further signals that CEO Steven Lo will be elevated to the Chairman role, which we would not support.

    While the Board's stated intent to adopt a director stock ownership policy to better align the Board's interests with stockholders is a long-overdue step in the right direction, it too fails to deliver meaningful change that long-suffering stockholders deserve. It is troubling to us that the Board announced these insufficient changes seemingly without soliciting input from stockholders.

    As a reminder, Vaxart previously claimed it would incorporate "stockholder feedback" into governance reforms; yet, these changes were announced unilaterally, without outreach to the very investors who have consistently called for transparency, accountability and structural reform at the Company. This decision follows the overwhelming rejection of the Company's proposed reverse stock split at the June 13, 2025 annual meeting of stockholders (twice adjourned after failing to receive stockholder support), apparent rejection of the reverse stock split at the originally scheduled September 5th special meeting and reinforces our concern that the Board will continue to disregard the will of stockholders.

    "This appointment does not reflect genuine change," said Mr. Houle, spokesperson for the Concerned Vaxart Stockholders. "Elevating Mr. Watson while disregarding stockholder voices only widens the trust deficit, as does seemingly perpetuating a misconception that Vaxart can only secure partnerships if it regains its Nasdaq listing via a reverse stock split. The Board should engage constructively with stockholders to chart a viable path forward that rebuilds trust and long-term value, rather than relying on titles and symbolic gestures in an attempt to placate them."

    The Concerned Vaxart Stockholders (1) urge all stockholders to remain vigilant and to continue voting "AGAINST" the reverse stock split proposal, which we believe risks obscuring underlying issues rather than addressing them, and (2) call on the Company to engage in genuine dialogue with its investor base, implement reforms that reflect stockholder priorities and restore credibility through meaningful action rather than optics.

    THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD. THE CONCERNED VAXART STOCKHOLDERS ARE NOT ASKING FOR YOUR PROXY CARD AND WILL NOT ACCEPT PROXY CARDS IF SENT. THE CONCERNED VAXART STOCKHOLDERS ARE NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

    Contact Information

    Daniel Houle

    lloyd19791@gmail.com

    (518) 222-3132



    Get the next $VXRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxart Urges Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

    Mails Letter to Shareholders Detailing Strength of the Board's Nominees and Momentum in Advancing Vaxart's Value Creation Strategy Reinforces that the Dissident's Nominees Have No Relevant Biotechnology or Public Company Leadership Experience and Their Appointment to the Board Would Be Value Destructive Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders urging them to vote "FOR" ALL si

    6/8/26 8:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

    Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing Vaxart's Highly Qualified Directors with Candidates Who Have No Relevant Expertise Urges Shareholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platf

    6/1/26 8:18:33 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

    Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform  Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 1

    5/19/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson W. Mark bought $6,530 worth of shares (10,000 units at $0.65), increasing direct ownership by 8% to 134,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    5/26/26 5:11:11 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Grasman Jeroen Nicolaas covered exercise/tax liability with 31,395 shares, decreasing direct ownership by 5% to 545,605 units (SEC Form 4) (tax liability)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    5/21/26 5:13:11 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Breitmeyer James B was granted 78,800 shares (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    5/1/26 8:55:09 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Vaxart with a new price target

    Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

    8/15/24 7:45:56 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Vaxart with a new price target

    Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

    12/29/21 7:23:57 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Vaxart with a new price target

    Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

    11/2/21 7:42:45 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson W. Mark bought $6,530 worth of shares (10,000 units at $0.65), increasing direct ownership by 8% to 134,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    5/26/26 5:11:11 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Elaine J bought $15,921 worth of shares (40,000 units at $0.40), increasing direct ownership by 71% to 96,566 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    11/21/25 1:21:51 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Vaxart Inc

    DEFA14A - Vaxart, Inc. (0000072444) (Filer)

    6/8/26 8:13:34 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Vaxart Inc

    DEFA14A - Vaxart, Inc. (0000072444) (Filer)

    6/1/26 5:10:05 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Vaxart Inc

    DEFA14A - Vaxart, Inc. (0000072444) (Filer)

    6/1/26 8:43:49 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

    Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform  Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 1

    5/19/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its business update and financial results for the first quarter of 2026. "In the first quarter of 2026, our team remained focused o

    5/7/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

    Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t

    4/23/26 4:30:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Financials

    Live finance-specific insights

    View All

    Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET

    Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced that members of the Company's senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026. The live fireside chat can be accessed by clicking here or on the Company's website at www.vaxart.com. Investors may submit written questions in ad

    5/1/26 8:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

    3/12/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart to Host Upcoming Conference Calls

    Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul

    3/3/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

    SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

    2/13/24 5:16:04 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vaxart Inc

    SC 13G - Vaxart, Inc. (0000072444) (Subject)

    1/19/24 4:30:58 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vaxart Inc

    SC 13G - Vaxart, Inc. (0000072444) (Subject)

    2/9/23 11:35:17 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care